Enanta Pharmaceuticals to Present at the SVB Securities Global Biopharma Conference

Rhea-AI Summary

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) announced that Jay R. Luly, Ph.D., President and CEO, will participate in a fireside chat at the SVB Securities Global Biopharma Conference on February 14, 2023, at 8:40 a.m. ET. The event will be accessible via a live webcast on Enanta's website, with a replay available for 30 days post-event. Enanta specializes in developing small molecule drugs for viral infections, including candidates for RSV, COVID-19, and hepatitis B virus. Their research is funded by royalties from hepatitis C virus products developed with AbbVie, including the leading treatment regimens MAVYRET® and MAVIRET®.

WATERTOWN, Mass.--(BUSINESS WIRE)-- Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the SVB Securities Global Biopharma Conference on February 14, 2023 at 8:40 a.m. ET.

A live webcast of the event will be accessible by visiting the “Events and Presentations” section on the “Investors” page of Enanta’s website at www.enanta.com. A replay of the webcast will be available following the presentation and will be archived for approximately 30 days.

About Enanta Pharmaceuticals, Inc.
Enanta is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs for the treatment of viral infections. Enanta’s research and development programs include clinical candidates for the following disease targets: respiratory syncytial virus (RSV), SARS-CoV-2 (COVID-19) and hepatitis B virus (HBV). Enanta is also conducting research on a single agent targeting both RSV and human metapneumovirus (hMPV).

Enanta’s research and development activities are funded by royalties from hepatitis C virus (HCV) products developed under its collaboration with AbbVie. Glecaprevir, a protease inhibitor discovered by Enanta, is part of one of the leading treatment regimens for curing chronic HCV infection and is sold by AbbVie in numerous countries under the tradenames MAVYRET® (U.S.) and MAVIRET® (ex-U.S.) (glecaprevir/pibrentasvir). Please visit www.enanta.com for more information.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230207005136/en/

Media and Investor Contact:

Jennifer Viera

617-744-3848

jviera@enanta.com

Source: Enanta Pharmaceuticals, Inc.

FAQ

When will Enanta Pharmaceuticals participate in the SVB Securities Global Biopharma Conference?

Enanta Pharmaceuticals will participate in the SVB Securities Global Biopharma Conference on February 14, 2023, at 8:40 a.m. ET.

How can I watch the Enanta Pharmaceuticals conference presentation?

You can watch the Enanta Pharmaceuticals conference presentation via a live webcast on their website in the 'Events and Presentations' section.

What are the main focuses of Enanta Pharmaceuticals' research and development?

Enanta Pharmaceuticals focuses on developing small molecule drugs for viral infections, including respiratory syncytial virus (RSV), COVID-19, and hepatitis B virus (HBV).

What products fund Enanta Pharmaceuticals' research activities?

Enanta Pharmaceuticals' research activities are funded by royalties from hepatitis C virus products developed in collaboration with AbbVie.

What are the trade names associated with Enanta's hepatitis C treatments?

The trade names associated with Enanta's hepatitis C treatments are MAVYRET® in the U.S. and MAVIRET® in other countries.